In short
This article explores the ongoing clinical trials of EO2463, an innovative microbial-derived peptide therapeutic vaccine being studied for the treatment of indolent Non-Hodgkin's Lymphoma. The trials aim to evaluate the safety, efficacy, and potential combinations of EO2463 with other treatments in patients with Follicular Lymphoma and Marginal Zone Lymphoma.
At a glance
- Drug Name
- EO2463
- Drug Type
- Microbial-derived peptide therapeutic vaccine
- Condition Studied
- Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
- Trial Phase
- Phase 1/2
- Primary Objectives
- Determine recommended dose, assess safety, evaluate objective response rate
- Administration
- Subcutaneous injection
- Combinations Studied
- EO2463 alone, with lenalidomide, with rituximab, and with both lenalidomide and rituximab
- Key Eligibility Criteria
- Adults (≥18 years), HLA-A2 positive, confirmed FL or MZL diagnosis
- Trial Duration
- 9-12 months active treatment, 24 months short-term follow-up, 5 years long-term follow-up
What is EO2463?
EO2463 is a new type of cancer treatment called a microbial-derived peptide therapeutic vaccine. It is currently being studied for the treatment of certain types of indolent Non-Hodgkin's Lymphoma (NHL), specifically Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL).
This innovative therapy is composed of several peptides (small protein fragments) named UCP2, OMP72, OMP64, OMP65, and OMP66. These peptides are derived from microbes and have been designed to stimulate the immune system to fight against lymphoma cells.
Target Conditions
EO2463 is being developed to treat two specific types of indolent (slow-growing) Non-Hodgkin's Lymphoma:
- Follicular Lymphoma (FL): A type of lymphoma that develops from B-lymphocytes (a type of white blood cell) in the lymph nodes.
- Marginal Zone Lymphoma (MZL): A group of lymphomas that also develop from B-lymphocytes. MZL includes three subtypes:
- Extranodal MZL (EMZL, also known as MALT lymphoma)
- Splenic MZL (SMZL)
- Nodal MZL (NMZL)
These lymphomas are considered "indolent" because they tend to grow and spread slowly compared to more aggressive forms of lymphoma.
How EO2463 Works
EO2463 is designed to work as a therapeutic vaccine, which means it aims to stimulate the patient's own immune system to recognize and attack cancer cells. The peptides in EO2463 are thought to mimic certain proteins found on lymphoma cells. When introduced into the body, these peptides may trigger an immune response against the lymphoma cells.
Specifically, EO2463 is designed to stimulate T cells (a type of immune cell) to recognize and target proteins found on B cells, including CD20, CD22, CD37, and BAFF-receptor. These proteins are often present on lymphoma cells, making them potential targets for immune attack.
Clinical Trial Details
EO2463 is currently being studied in a Phase 1/2 clinical trial. This trial is designed to evaluate the safety and effectiveness of EO2463 in patients with indolent Non-Hodgkin's Lymphoma. The study is exploring EO2463 as a standalone treatment and in combination with other drugs:
- EO2463 alone (monotherapy)
- EO2463 combined with lenalidomide (a drug that modifies the immune system)
- EO2463 combined with rituximab (an antibody therapy that targets B cells)
- EO2463 combined with both lenalidomide and rituximab
The trial is divided into two phases:
- Phase 1: This phase aims to determine the safe and recommended dose of EO2463 for further study.
- Phase 2: This phase will evaluate how well EO2463 works in treating lymphoma, primarily by measuring the objective response rate (ORR). The ORR is the percentage of patients whose cancer shrinks or disappears after treatment.
Potential Benefits
While the effectiveness of EO2463 is still being studied, the researchers hope to see several potential benefits:
- Shrinkage or disappearance of lymphoma (measured as objective response rate)
- Longer time before the lymphoma progresses or requires additional treatment
- Improved overall survival
- A new treatment option for patients who have relapsed after previous therapies
It's important to note that these potential benefits are still being investigated in the clinical trial.
Safety Considerations
As with any new treatment, safety is a crucial consideration. The clinical trial is carefully monitoring patients for any side effects or adverse events. Some specific safety considerations include:
- Potential immune-related side effects, as EO2463 stimulates the immune system
- Interactions with other medications, particularly when EO2463 is combined with lenalidomide and/or rituximab
- Effects on blood cell counts and immune system function
Patients in the trial are closely monitored for any adverse events, which are graded according to standardized criteria to ensure patient safety.
Eligibility Criteria
The clinical trial has specific criteria for patient eligibility. Some key points include:
- Patients must be 18 years or older
- Patients must have confirmed Follicular Lymphoma or Marginal Zone Lymphoma
- Patients must be HLA-A2 positive (a specific genetic marker)
- Some patients must have received prior treatment, while others must be newly diagnosed (depending on the study cohort)
- Patients must meet certain health criteria, including adequate organ function and performance status
There are also several exclusion criteria, such as certain prior treatments, other medical conditions, or specific laboratory test results that would prevent participation.
It's important to note that EO2463 is still an investigational treatment. While it shows promise, its safety and effectiveness are still being evaluated in clinical trials. Patients interested in this treatment should discuss it with their healthcare provider to understand if it might be an appropriate option for them.